Introduction
Deep vein thrombosis (DVT) is a common condition that is characterized by the formation of an occlusive blood clot in the venous vascular system, which occurs most often in the large veins of the legs (Schulz et al., 2013) . DVT and its various adverse outcomes, including pulmonary embolism, are the third leading cause of cardiovascular-associated death after myocardial infarction and stroke (Mackman, 2008; Mackman, 2012) . Tissue factor (TF) is a key trigger of blood coagulation and an important determinant of the hypercoagulable state that is associated with venous thrombosis (Li et al., 2009; Mackman, 2012) . Inhibition of TF may represent an effective strategy for DVT treatment (Mackman, 2012; Zhai et al., 2015) .
Non-muscle myosin II is an actin-based motor protein that is essential for a variety of physiological and pathological functions (Liu et al., 2010; Maravillas-Montero and Santos-Argumedo, 2012; Lv et al., 2013; Badirou et al., 2015) . Non-muscle myosin heavy chain IIA (NMMHC IIA) is one of the isoforms of non-muscle myosin II, and earlier studies have suggested that its deficiency or inhibition can reduce platelet aggregation, TF expression and arterial thrombus formation (Calaminus et al., 2007; Leon et al., 2007; Ono et al., 2008) . Our recent study has shown that NMMHC IIA inhibition or knockdown decreases TF expression and DVT mainly through the Akt/GSK3β-NF-κB signalling pathway. NMMHC IIA inhibition or stabilization of the NMMHC IIA-TNF receptor II (TNFR2) interaction is a novel potential strategy for the treatment of venous thrombosis and other inflammation-related thrombotic diseases (Zhai et al., 2015) .
Natural products, as used in traditional Chinese medicine, are a major resource for drug discovery as they include a wide variety of chemicals with structural diversity and novel molecular scaffolds. Ophiopogon japonicus and Liriope muscari are two traditional Chinese herbs that have been widely used throughout history in China to treat acute and chronic inflammatory diseases, as well as cardiovascular diseases. Recent evidence suggests that saponins, including ruscogenin, ophiopogonin D and DT-13, found in extracts of these two herbs are involved in anti-inflammatory and anti-thrombotic activity, as well as inhibition of TF (Liu et Sun et al., 2012; Tian et al., 2013) . Furthermore, our previous study indicated that saponin compounds are potential NMMHC IIA inhibitors, based on NMMHC IIA homology modelling and virtual screening (Lv et al., 2013) . In addition, we have used molecular docking and an in vitro assay to comprehensively evaluate the effects of 16 ophiopogon saponin derivatives that were isolated from L. muscari, on NMMHC IIA binding energy and TF expression. The results revealed that eight compounds showed good binding affinity to NMMHC IIA and markedly downregulated TF protein expression. Among them, D39 (whose chemical structure is shown in Figure 1A ) showed the lowest binding energy for NMMHC IIA and significantly downregulated TF expression (Supporting Information Figure  S1 ). In the present study, we have investigated the effects and underlying mechanisms of D39 on NMMHC IIAdependent TF expression and DVT. Our studies showed that D39 down-regulated endothelial TF expression and venous thrombus formation by modulating the PI3K/Akt/GSK3β and NF-κB signalling pathways. Molecular docking analysis and serial affinity chromatography indicated the possible binding of D39 to NMMHC IIA, which was confirmed by the gain-of-function and loss-of-function studies of NMMHC IIA in HEK293T cells and HUVECs. In addition, D39 inhibited the dissociation of NMMHC IIA from TNFR2 both in vitro and in vivo. These findings suggested that NMMHC IIA mediated the anti-thrombotic activity of D39 and that D39 could be a potential therapy for DVT and other vasculopathies.
Methods

Cell culture
HUVECs, primary HUVECs, EA.hy 926 endothelial cells and HEK 293T cells were maintained at 37°C in a humidified incubator with 5% CO 2 and were cultured in growth medium (DMEM). EA.hy 926 endothelial cells and HEK 293T were from American Type Culture Collection (Manassas, VA, USA). HUVECs and primary HUVECs (Lot Number 5138) were from Sciencell Research Laboratories, Inc. (Carlsbad, CA, USA). The companies have ethical permission for work with human tissue and the patients' permissions to use the cells. 
Tables of Links
Western blot analysis
Cell lysates were prepared, and protein concentrations were determined by the bicinchoninic acid protein assay. Equivalent amounts of total proteins were separated by 10% SDS-PAGE, subjected to immunoblotting, probed with the respective antibodies and detected using HRP-conjugated secondary antibodies coupled with ECL.
Molecular docking
All ligands were constructed in Sybyl x1.1 and then applied to all hydrogen and Gastiger-Huckel charges in Sybyl in the Tripos force field under an implicit solvent environment. The minimization steps included 1000 cycles of the steepest descent until the convergent threshold of 0.05 kcal À1 ·Å
À1
was satisfied. All ligands were docked into the binding site of a homology model of NMMHC IIA (Lv et al., 2013) via GOLD 3.0.1. The centre of the grid was placed at the centre of the receptor binding site, with grid dimensions of (15, 15, and 15 Å). Ten conformers were generated from random configurations of the ligand with fully flexible torsion degrees of freedom. The GoldScore function of GOLD 3.0.1 was employed to estimate the binding energies (Trott and Olson, 2010) . The indices were chosen as twice the speed calculation, while Van der Waals forces and hydrogen bonding parameters were set to 6.0 and 3.0 respectively. The highest score ranked by GoldScore and ChemScore was chosen for further research (Banerji et al., 2007) .
Simplified chromogenic assay
The cell lysates were frozen and thawed three times before they were used in the assay. The cell surfaces were washed three times by PBS. Mouse plasma was prepared by centrifugation at 3000× g for 10 min and stored at À70°C before use. TF activity was determined by a chromogenic assay as previously reported (Sun et al., 2012) . Samples (45 μL) were incubated with Tris-CaCl 2 buffer (5 μL, pH 7.3) containing human prothrombin complex in a 96-well plate and Figure 1 D39 suppressed TNF-α-induced TF expression and procoagulant activity in HUVECs. HUVECs were pretreated with D39 for 1 h at various concentrations followed by TNF-α (10 ng·mL À1 ) stimulation for 5 h. (A) The structure of saponin D39. (B) TF mRNA expression levels after TNF-α exposure, with or without D39 (0.01-1 μM). (C, D) TF protein expression was analysed by Western blots and immunofluorescence. (E) TF procoagulant activities in cell lysates were examined with a chromogenic assay. Data shown are the means ± SEM of five independent experiments. # P < 0.05, significantly different from the unstimulated group; *P < 0.05, significantly different from the TNF-α-stimulated group. 
Serial affinity chromatography
Separation and identification of target proteins using serial affinity chromatography was performed as described previously with some modifications (Yamamoto et al., 2006; Ju et al., 2012) . Briefly, lysate from endothelial cells (1.0 mL) was stirred gently with the D39 affinity resin (30 μL) (Epoxy activated-Sepharose ™ 6B, EAS6B, GE Healthcare) at 4°C for approximately 1.5 h and was then precipitated by centrifugation at 16 000 × g for 1 min. The resulting supernatant was mixed with another 30 μL of the D39 affinity resin at 4°C, again for approximately 1.5 h. The resulting resin was washed three times with 1.0 mL of lysate buffer, resuspended in 30 μL of 2 × loading buffer, heated in boiling water for 5 min and then centrifuged for 1 min. The supernatant was subjected to SDS-PAGE. The resulting bands were stained with silver staining and then comparatively analysed to identify specific binding proteins. For reproducibility, the above procedures were carried out 3-5 times.
Human NMMHC IIA knockdown
As described in our previous report (Zhai et al., 2015) , the sequences of the siRNAs used to suppress NMMHC IIA expression were 5-GAGGCAAUGAUCACUGACUdTdT-3 and 5-AGUCAGUGAUCAUUGCCUCdTdT-3, and they were designed and synthesized by Biomics Biotechnologies Co., Ltd. (Nantong, Jiangsu, China). Endothelial cells were seeded in 60 mm dishes and grown to 70-80% confluence, and then they were transfected with siRNA using ExFect Transfection Reagent. Final concentrations of siRNA or non-silencing siRNA were 100 nM.
Human NMMHC IIA overexpression
The recombinant plasmid pEGFP-NMMHC IIA (EX-T1335-M98) was constructed by the directed cloning technique according to FulenGen (Guangzhou, China). For plasmid transfection, HEK 293T cells were plated on 6-well plates at a density of 4 × 10 5 cells per well. Transfection of HEK 293T cells was performed using the Endofectin Transfection Reagent (FulenGen, Guangzhou, China) according to the manufacturer's instructions. Briefly, 3 μg of purified pEGFP-NMMHC IIA diluted in 200 μL of Opti-MEM medium was mixed with 9 μg of Endofectin Transfection Reagent that was diluted in 200 μL of Opti-MEM medium. The DNAEndofectin mixture was incubated for 20 min at room temperature and then added to the 6-well plates. Four hours later, the medium was changed to complete medium. Control cells were mock-transfected with empty vectors as a negative control (Zhai et al., 2015) .
Co-immunoprecipitation
The primary HUVECs were lysed in RIPA lysis buffer (25 mM Tris•HCl pH 7.6, 150 mM NaCl, 1% NP-40, 1% sodium deoxycholate and 0.1% SDS) containing protease inhibitor (aprotinin, bestatin, E-64, leupeptin, sodium, orthovanadate, sodium pyrophosphate and β-glycerophosphate). Anti-NMMHC IIA and TNFR2 antibody (Abcam, CA, USA) together with protein A/G agarose were used to immunoprecipitate TNFR2 and NMMHC IIA, respectively, as well as associated proteins. Proteins were resolved by SDS-PAGE and detected by Western blot analysis.
Proximity ligation assays (PLA)
To demonstrate a complex between native TNFR2 and NMMHC IIA in primary HUVECs, a PLA kit (Sigma-Aldrich, St Louis, USA) was used according to the manufacturer's protocols (Soderberg et al., 2008) . Primary antibodies against TNFR2 and NMMHC IIA were used, and secondary antibodies were conjugated to oligonucleotides for ligation and subsequent rolling-circle amplification.
Animals
All animal care and experimental procedures were carried out according to the current European Communities Council-ECC guidelines for the care of laboratory animals and ethical guidelines for investigations of experimental pain in conscious animals. In addition, Ethical approval was granted by the Animal Welfare and Ethics Review Board of the University of Bristol, UK. Animal studies are reported in compliance with the ARRIVE guidelines (Kilkenny et al., 2010; McGrath & Lilley, 2015) . Male C57BL/6J mice (20-25 g; 8 weeks; specified pathogen free) were provided by the Model Animal Research Centre of Yangzhou University (Yangzhou, Jiangsu, China) and kept in cages containing standard bedding, with at least five mice per cage. Mice were housed in a specific pathogen-free facility with 12 h light/dark cycle [07 to 19 h, temperature (22 ± 2°C), humidity (40-70%), controlled ventilation] and with sterile water and irradiated food available ad libitum. Animals were allowed to acclimatize to their housing environment for at least 7 days prior to experimentation and to the experimental room for 1 h before experiments.
Mouse models of deep vein thrombosis
The mice were randomly divided into five groups: sham, those with inferior vena cava ligation (IVCL), IVCL + 0.1 mg·kg À1 D39, IVCL + 0.3 mg·kg À1 D39 and IVCL + 1 mg·kg À1 D39.
The mice were injected with vehicle (5% ethanol in saline) or D39 (0.1, 0.3 or 1 mg·kg À1 ) i.p. and then underwent IVCL to initiate thrombus formation 1 h later. Before surgery, mice were anaesthetized with ketamine and xylazine (80 mg·kg À1 and 10 mg·kg À1 , respectively, i.p.) and a midline laparotomy was performed (Singh et al., 2002; Zhai et al., 2015) . The small bowel was exteriorized and placed onto a moistened gauze pad next to the animal. The infrarenal IVC was identified, and all side branches were ligated with nonreactive 6-0 Prolene suture. Posterior venous branches were cauterized. A 6-0 Prolene suture was tied down on the IVC, caudally to the left renal vein. After surgery, peritoneum and skin were closed by monofilament suture with asepsis. The animal allowed to recover with good postoperative care, according to the current European Communities Council ECC guidelines for the care of laboratory animals and ethical guidelines for investigations of experimental pain in conscious animals. The post-operative death rate was about 15%. The mice were killed 48 h after IVCL and plasma and the IVC were collected for analysis.
The experiment was performed in a blinded manner.
Histology and immunohistochemistry
The excised vessel was dehydrated with 40% sucrose, embedded in optimal cutting temperature (OCT) and frozen at À70°C. The IVC was sectioned into slices of 10 μm of thickness with a cryotome (Leica, Mannheim, Germany). Specimens were washed in PBS and stained with haematoxylin and eosin (H&E). For immunohistochemical staining, slides were incubated with primary antibodies at 4°C overnight. Alexa Fluor 488-/594-labelled antibodies were used as secondary antibodies. The nuclei were stained with DAPI. Pathological changes in IVC were observed under a fluorescence microscope (Leica, Mannheim, Germany).
Data and statistical analysis
The data and statistical analysis in this study comply with the recommendations on experimental design and analysis in pharmacology (Curtis et al., 2015) . Results are reported as the mean ± SEM. The data were analysed by two-tailed Student's t-test or one-way ANOVA followed by Dunnett post hoc tests. A P value < 0.05 was considered statistically significant. Data analysis was conducted in blinded manner (single-blind study design).
Materials
The saponins ruscogenin, ophiopogonin D, DT-13, D39, D5, D23, D26, D36, D21, D29, D31, D32, D41, D28, D34-22 and D34-27 (purity > 95%) were extracted and purified from extracts of the root tuber of L. muscari by the authors. Stock solutions (50 μM) were made in DMSO and stored at À20°C. FBS was purchased from Invitrogen (Grand Island, NY, USA). DMEM was from GIBCO/BRL (Life Technologies, CA, USA 
Results
D39 significantly down-regulated TF expression and inhibited procoagulant activity in HUVECs
To further confirm the effects of D39 on TF expression and activity in endothelial cells, the cells were pretreated with D39 (0.01, 0.1 or 1 μM) to suppress TF mRNA and to down-regulate its expression, which is triggered by TNF-α (10 ng·mL À1 ) in HUVECs in a dose-dependent manner ( Figure 1B, C) . Immunocytochemistry analysis also confirmed that D39 treatment down-regulated TF expression in HUVECs that were stimulated with TNF-α ( Figure 1D ). Similarly, D39 inhibited the procoagulant activity of TF, as determined by a simplified chromogenic assay ( Figure 1E ).
D39 activated the Akt/GSK3β signalling pathway and inhibited NF-κB p65 nuclear translocation in HUVECs
The PI3K/Akt signalling pathway negatively regulates TF expression in vitro and in vivo. In our present experiments, D39 pretreatment significantly up-regulated phospho-PI3K, phospho-Akt and phospho-GSK3β in TNF-α-treated cells (Figure 2A-C) . To further determine whether TF expression is also modulated by the PI3K/Akt/GSK3β signalling pathway in endothelial cells, we examined TNF-α-induced TF expression in the presence of the PI3K inhibitor wortmannin or the GSK3β inhibitor CHIR99021. The results showed that wortmannin blocked the inhibitory action of D39 (Supporting Information Figure S3B ) and CHIR99021 enhanced the inhibitory effects of D39 on TF expression (Supporting Information Figure S3A ), indicating that D39 reduced TF expression through PI3K/Akt signalling by suppressing GSK3β activity. NF-κB/p65 is a transcription factor that regulates TF expression. Inactivated GSK 3β (p-GSK 3β) prevents degradation of IκBα and p65 nuclear translocation (Guha and Mackman, 2002; Zhang et al., 2010) . As shown in Figure 2D , E, TNF-α induced IκBα phosphorylation and IκBα degradation, but these effects were inhibited by D39. TNF-α-induced NF-κB p65 phosphorylation was also attenuated by D39 ( Figure 2F ). D39 abolished the TNF-α-induced nuclear localization of p65 in primary HUVECs, and its expression was similar to that in controls ( Figure 2G, H) . This suggested a key role for D39 in down-regulating TF expression via the NF-κB pathway ( Figure 2G, H) .
NMMHC IIA mediated the inhibitory effects of D39 on TF expression
Using the D39 affinity medium, we captured specific binding proteins for D39 from HUVEC lysates by serial affinity chromatography, as illustrated in Figure 3A . The amount of Cells were pretreated with 1 μM D39 for 1 h and stimulated with TNF-α (10 ng·mL
À1
) for 30 min. Proteins were extracted from the cytoplasm and nucleus, using β-actin and histone H3 as the internal standards. Data shown are the means ± SEM (n = 5 in five individual experiments) for the cell line experiments. # P < 0.05, significantly different from the unstimulated group; *P < 0.05, significantly different from the TNF-α-stimulated group. Figure S2 ), suggesting that NMMHC IIA might be a specific binding protein of D39.
~230 kD protein, as indicated by SDS-PAGE, obviously decreased following serial affinity chromatography. MALDI-TOF-MS and Western blot analysis of the~230 kD protein identified it as NMMHC IIA (Supporting Information
The docking study was carried out to explore the interaction of D39 with NMMHC IIA via GOLD 3.0.1. The docking results showed that 10 output conformers of the complex for D39 and NMMHC IIA had similar binding modes. The scaffold triterpene of D39 extended deep into the hydrophobic pocket of NMMHC IIA ( Figure 3B ), which interacted with Figure 3D , NMMHC IIA overexpression in HEK293T cells significantly up-regulated TF expression. However, D39 (1 μM) markedly downregulated TF expression in HEK293 cells that overexpressed NMMHC IIA. In addition, NMMHC IIA was successfully knocked down by an siRNA that specifically targeted MYH9 without affecting other myosin subtype expression in endothelial cells [data were shown in our previous report (Zhai et al., 2015) ]. NMMHC IIA knockdown significantly down-regulated TNF-α-induced TF protein expression ( Figure 3E ). Meanwhile, D39 significantly down-regulated TNF-α-induced TF protein expression in the negative-siRNA group but not in the MYH9-siRNA group.
D39 inhibited the disassociation of NMMHC IIA and TNFR2 in primary HUVECs
As previously documented (Zhai et al., 2015) , NMMHC IIA bound to TNFR2 and mediated signal internalization in TNF-α-stimulated endothelial cells. To investigate the inhibitory effect of D39 on NMMHC IIA in the regulation of TNFR2 signalling, we examined the potential protein-protein interaction (PPI) between NMMHCIIA and TNFR2 in untreated and TNF-α-stimulated primary HUVECs. As shown in Figure 4A , B, TNFR2 was co-localized and co-immunoprecipitated with NMMHCIIA in untreated cells, but not after TNF-α-stimulation. D39 inhibited the TNF-α-stimulated dissociation of NMMHC IIA from TNFR2. Similar results were obtained by the Duolink Proximity ligation assay ( Figure 4C ). These results suggest that TNF-α-stimulation disrupts the interaction between NMMHC IIA and TNFR2 and activates TNF-α-dependent signal internalization. Also D39 inhibits the TNF-α-stimulated dissociation of NMMHC IIA from TNFR2.
D39 inhibited venous thrombosis and plasma TF activity in vivo
To evaluate the effects of D39 on venous thrombus formation, the IVCL mouse model was utilized. The thrombus weight to length ratio was clearly increased in the IVCL mouse model compared with the sham group. Pretreatment with D39 reduced the thrombus weight to length ratio in a dose-dependent manner ( Figure 5A, B) . Meanwhile, H&E staining of the venous cross-section showed that the IVCL procedure led to dramatic thrombus formation after 48 h in mice treated with vehicle, as determined by the presence of a red thrombus ( Figure 5D ). In contrast, D39 administered at different doses significantly inhibited venous thrombosis. In addition, plasma was collected from the mouse eye socket as described previously (Zhai et al., 2015) . We further investigated the inhibitory effects of D39 on plasma TF procoagulant activity. A simplified chromogenic assay showed that D39 decreased plasma TF procoagulant activity in a dose-dependent manner ( Figure 5C ).
D39 suppressed endothelial TF expression by modulating GSK3β/p65 signalling pathways through inhibiting the dissociation of NMMHC IIA from TNFR2 in vivo
In the IVC-ligated mice, we assessed the effects of D39 on endothelial TF expression. As illustrated in Figure 6A , B, D39 (0.1-1 mg·kg À1 ) inhibited endothelial TF expression in the IVCL group in a dose-dependent manner. Furthermore, we also investigated the effects of D39 on GSK3β and p65 activation. D39 significantly up-regulated phospho-GSK3β ( Figure 6C ) and down-regulated p65 expression ( Figure 6D ). Moreover, to confirm the interaction between NMMHC IIA and TNFR2 that was modulated by D39, we then examined whether D39 could inhibit the dissociation of NMMHC IIA from TNFR2 in vivo. As shown in Figure 6E , TNFR2 was colocalized with NMMHCIIA in sham-operated mice but not in IVC-ligated mice, and D39 inhibited the IVCL-induced dissociation of NMMHC IIA from TNFR2.
Discussion
The endothelium is one of the most important components in the pathogenesis of thrombotic and atherosclerotic disease (Ramot et al., 2013) . Endothelial cells also produce a variety of substances that regulate vessel tone, permeability, coagulation and fibrinolysis (Wakefield et al., 2008) . Adherence of cells and fibrin to intact endothelium is rarely seen. However, when the blood vessel wall is injured, the subendothelium is revealed. Platelets and other blood cells will immediately attach to the subendothelium, and the blood coagulation system becomes activated and forms clots (Mackman, 2012) . In our previous study, we had demonstrated that the endothelial lining of blood vessels played a critical role in regulating thrombosis by preventing procoagulant and proinflammatory activities. NMMHC IIA in endothelial cells was a key upstream protein involved in TF expression and DVT. Inhibition or knockdown of endothelial NMMHC IIA decreased TF expression and thrombus formation, and this was mainly achieved through the Akt/GSK3β-NF-κB signalling pathway (Zhai et al., 2015) . However, there are not yet any natural antithrombotic products that target NMMHC IIA. In this paper, based on molecular docking to NMMHC IIA and TF expression screening using 16 compounds from L. muscari, we identified a novel saponin D39 that downregulated expression of TF, in low concentrations (1 μM) (Supporting Information Figure S1 ). This was also the first time that we had demonstrated the anti-thrombotic activity of D39 in IVC-ligated mice ( Figure 5) .
Our current study further demonstrated that NMMHC IIA was a potential target of D39, mediating its anti-thrombotic effects. D39 down-regulated TF expression and reduced DVT formation in vitro and in vivo through activation of the Akt/GSK3β signalling pathway and inhibition of the NF-κB signalling pathway (Figures 1, 2 , 5 and 6), which was consistent with the results using the known NMMHC IIA inhibitor, blebbistatin (Zhai et al., 2015) . However, it was unclear whether the pharmacological effects of D39 were mediated through its effects on NMMHC IIA. NMMHC IIA overexpression up-regulated TF expression in HEK293T cells, which was significantly reversed by D39 (1 μM). NMMHC IIA knockdown downregulated TNF-α-induced TF protein expression, while D39 did not affect TNF-α-induced TF protein expression in the MYH9-siRNA group (Figure 3) . These findings indicated that the inhibitory activity of D39 on TF expression was dependent on NMMCH IIA. Furthermore, interactions between D39 and NMMHC IIA were assessed by serial affinity chromatography and molecular docking. Serial affinity chromatography is a classical pulldown method that has been applied to identify the targets of biologically active compounds in cell or tissue lysates (Terstappen et al., 2007; Ziegler et al., 2013) . The low MW ligand (probe) is immobilized on a solid phase and exposed to a protein extract (cell or tissue lysates) to bind the target protein(s). Subsequently, proteins that bind nonspecifically to the probe and the matrix are removed by stringent washing prior to release of the bound proteins by eluting with a bioactive molecule or by heating. Finally, the target proteins are typically separated by SDS-PAGE and identified by immunodetection or mass spectrometry (Margarucci et al., 2011; Margarucci et al., 2013) . Our results demonstrated that NMMHC IIA could be pulled down by D39 in cell lysates ( Figure 3A and Supporting Information Figure S2 ). As previously documented, the myosin II holoenzyme consists of two molecules of myosin heavy chain (NMMHC II) and one molecule of the myosin regulatory light chain (MRLC,~20 kDa) and the myosin essential light chain (MELC,~17 kDa) associated with each NMMHC II at the neck region (Conti and Adelstein, 2008; Heissler and Manstein, 2013) . Therefore, together with NMMHC IIA, low molecular weight MRLC and MELC ( Figure 3A) should also be easily pulled down, which was confirmed in the previous report (Chandrasekharan et al., 2013) . In addition, molecular docking was used to accurately predict the structure of the ligand within the constraints of a receptor binding site and estimate the strength of binding (Yuriev and Ramsland, 2013) . The docking results showed that all the parts of D39 extended deep into the hydrophobic pocket of NMMHC IIA ( Figure 3B ) and formed H-bonds ( Figure 3C ), which further confirmed the binding affinity of D39 to NMMHC IIA.
Of note, PPIs play a key role in various biological processes (Zarzycka et al., 2016) . Similar to PPI inhibition, stabilization of dimers or oligomers can lead to either the activation or inhibition of a biological function. However, the stabilization of PPI complexes with low MW compounds (i.e. targeting regions at or near the interfaces of two or more proteins) can benefit from significantly higher specificity (Thiel et al., 2012) . Most of the low MW compounds that have been identified to modulate PPIs are inhibitors. Another promising way to interfere with PPI-associated biological processes is to promote PPI stabilization. Although PPI stabilizers are still scarce, stabilization of PPIs by low MW compounds is gaining momentum and offers new pharmacological options (Zarzycka et al., 2016) . Our findings also demonstrated that D39 combined with NMMHC IIA to inhibit the dissociation of NMMHC IIA from TNFR2 (Figure 4) , which was first reported using natural products. However, the particular functional domains of NMMHC IIA that interact with D39 remain undefined. Blebbistatin is a powerful inhibitor of myosin IIA ATPase activity (Straight et al., 2003; Kovacs et al., 2004) but our findings demonstrated that D39 did not affect myosin II ATPase activity (data not shown), based on Figure 6 D39 suppressed endothelial TF expression by modulating the GSK3β/p65 signalling pathways through inhibiting the dissociation of NMMHC IIA from TNFR2 in vivo. (A) IVC frozen sections were prepared, and TF expression was analysed by immunofluorescence. (B) IVC lysates were prepared, and TF expression was analysed by Western blots. (C, D) IVC lysates were prepared, and p-GSK3β, GSK3β and p65 expressions were analysed by Western blots. (E) IVC frozen sections were prepared and used for PLA to confirm NMMHC IIA-TNFR2 interaction (red signal), CD31 staining (green) and DAPI staining (blue). Data shown are the means ± SEM of five mice per group. # P < 0.05, significantly different from the sham group; *P < 0.05, significantly different from the IVCL group.
a previous experiment (Chen et al., 2016) . It is possible that the functional domains of NMMHC IIA that interact with blebbistatin and D39 may be different. This possibility requires further investigation. Another saponin similar to D39, DT-13, exhibits no significant genotoxicity, acute toxicity or subchronic 90 day toxicity (Ma et al., 2011) , which suggest that D39 may have a comparable safety level. These results indicate that D39 is probably one of the most important candidate natural products for the prevention and treatment of DVT. However, D39 is characterized by poor solubility and bioavailability , which limits its pharmacological effects in vivo. In our experiments, D39 was delivered to mice, dissolved in 5% ethanol-saline, by i.p. injection. The dose of D39 in vivo was determined by a series of pilot experiments and a DT-13 preliminary study (Ma et al., 2011) . Furthermore, we tried to use aspirin or heparin sodium injection (1500 IU/kg) as a positive control (data not shown). The death rate of mice was clearly increased by i.p. injection of heparin sodium, due to severe postoperative bleeding. However, D39 or aspirin did not cause obvious bleeding. Previously, we found that the ethanol extract of Radix O. japonicus decreased the dried weight of venous thrombi, although with no effects on activated partial thromboplastin time, thrombin time and prothrombin time. These results indicated that D39 might inhibit thrombosis without affecting the anti-coagulation pathways (Kou et al., 2005) . The stability and pharmacokinetics of D39 in vivo will need to be addressed in further studies.
In the current study, we explored the effects of D39 on NMMHC IIA in the endothelial cells in terms of the pathogenesis of DVT in vitro and in vivo. However, NMMHC IIA is expressed not only in the endothelium (Chandrasekharan et al., 2013) but also in monocytes/macrophages (Morrison et al., 2014) and platelets (Leon et al., 2007) . Because of the complex pathological process of DVT, endothelium and other blood cells were key effector cells involved in DVT. Therefore, it is possible that D39 could also affect NMMHC IIA in monocytes/macrophages, and even neutrophils in vivo. This possibility is definitely worth further examination.
In summary, our findings uncovered a key role for D39 in inhibiting TF expression and activity through modulating NMMHC IIA-TNFR2 interaction and subsequently modulating the Akt/GSK3β-NF-κB signalling pathways (Figure 7) . These results suggest that D39 might be useful in the clinical treatment of venous thrombosis and other inflammationrelated vasculopathies. Our findings also provide a better understanding of the pharmacological activities of natural products, such as steroid saponins, on PPIs. 
